Streetbeat News

ASND

Ascendis Pharma A/S

Industry

Biotechnology

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Open

153.65

Mkt cap

9.1B

Volume

444K

High

155.44

P/E Ratio

-22.38

52-wk high

161.00

Low

151.96

Div yield

N/A

52-wk low

111.09

Ascendis Pharma A/S (ASND) held its Q4 2024 earnings call on February 12, 2025, discussing financial results and company updates. Key participants included executives and analysts from major financial institutions.

Portfolio Pulse from

February 13, 2025 | 4:15 am

Ascendis Pharma reported its Q4 and full-year 2024 financial results, highlighting a strong early U.S. launch of YORVIPATH with 908 prescriptions by February 7, 2025, and full-year 2024 revenue of €28.7 million.

Portfolio Pulse from

February 12, 2025 | 9:15 pm

Ascendis Pharma A/S has announced a share repurchase program, planning to use approximately $25 million in the first quarter of 2025 to preserve around 200,000 ADSs as treasury shares.

Portfolio Pulse from

February 12, 2025 | 9:15 pm

Ascendant Resources has closed the first tranche of a private placement to fund the Lagoa Salgada Project and reduce short-term payables. This is part of an arrangement with Cerrado Gold, which plans to acquire all Ascendant shares.

Portfolio Pulse from

February 11, 2025 | 10:15 pm

Ascendis Pharma's TransCon technology platform is gaining traction with a new deal with Novo Nordisk for a monthly GLP-1 treatment in obesity, which includes $285M in milestones and royalties. Ascendis' products Skytrofa and Yorvipath are showing steady growth, with Q3 revenue of $62.4M.

Portfolio Pulse from

January 29, 2025 | 4:45 pm

Ascendis Pharma is gaining attention due to its promising developments and strong pipeline, with several commercial stage products indicating robust growth potential.

Portfolio Pulse from

January 29, 2025 | 5:45 am

Ascendis Pharma A/S has announced the commercial availability of YORVIPATH® (palopegteriparatide) in the United States for treating hypoparathyroidism in adults. This is the first FDA-approved medicine for this condition, marking a significant milestone for the company.

Portfolio Pulse from

December 19, 2024 | 1:45 pm

The InsiGHTS trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome achieved its primary objective at Week 26, demonstrating a safety and tolerability profile comparable to daily somatropin across all starting dose cohorts.

Portfolio Pulse from

December 16, 2024 | 1:45 pm

Ascendis Pharma's supplemental Biologics License Application for TransCon hGH, aimed at treating adult growth hormone deficiency, has been accepted by the FDA. The PDUFA goal date is set for July 27, 2025.

Portfolio Pulse from

December 12, 2024 | 9:15 pm

Er-Kim has extended its exclusive distribution agreement with Ascendis Pharma A/S to expand the commercialization of its endocrinology portfolio to Eurasian markets. This agreement involves the distribution of three rare endocrinology disease treatments.

Portfolio Pulse from

December 10, 2024 | 12:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.